Drugs / APR003
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04645797 | Jan 2021 → May 2022 | colorectal carcinoma | Apros Therapeutics, Inc | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APR003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04645797 ↗ |
| Action | Activate | “APR003 is a small molecule TLR7 agonist” NCT04645797 ↗ |
| Modality | Small molecule | “APR003 is a small molecule TLR7 agonist” NCT04645797 ↗ |
| Target | TLR7 | “APR003 is a small molecule TLR7 agonist” NCT04645797 ↗ |